These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 22439841

  • 1. Anti-obesity drugs: a review about their effects and their safety.
    Derosa G, Maffioli P.
    Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
    [Abstract] [Full Text] [Related]

  • 2. New and emerging drug molecules against obesity.
    George M, Rajaram M, Shanmugam E.
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
    [Abstract] [Full Text] [Related]

  • 3. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL, Bello NT.
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [Abstract] [Full Text] [Related]

  • 4. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S, Dear A, Cowley MA.
    Obes Res Clin Pract; 2017 Jun; 11(5):501-521. PubMed ID: 28818558
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological therapies for obesity.
    Kaplan LM.
    Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
    [Abstract] [Full Text] [Related]

  • 6. Obesity: new perspectives and pharmacotherapies.
    Palamara KL, Mogul HR, Peterson SJ, Frishman WH.
    Cardiol Rev; 2006 Mar; 14(5):238-58. PubMed ID: 16924165
    [Abstract] [Full Text] [Related]

  • 7. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Krentz AJ, Fujioka K, Hompesch M.
    Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
    [Abstract] [Full Text] [Related]

  • 8. Pharmacotherapy for obesity in individuals with type 2 diabetes.
    Chukir T, Shukla AP, Saunders KH, Aronne LJ.
    Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
    [Abstract] [Full Text] [Related]

  • 9. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 10. Update on obesity pharmacotherapy.
    Bray GA, Ryan DH.
    Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
    [Abstract] [Full Text] [Related]

  • 11. Pharmacotherapy for obesity.
    Ioannides-Demos LL, Proietto J, McNeil JJ.
    Drugs; 2005 Apr; 65(10):1391-418. PubMed ID: 15977970
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The incretin pathway as a new therapeutic target for obesity.
    Barber TM, Begbie H, Levy J.
    Maturitas; 2010 Nov; 67(3):197-202. PubMed ID: 20655673
    [Abstract] [Full Text] [Related]

  • 14. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
    Rubio MA, Gargallo M, Isabel Millán A, Moreno B.
    Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
    [Abstract] [Full Text] [Related]

  • 15. Anorectic state of obesity medications in the United States. Are leaner times ahead?
    Li X, Bello NT.
    Expert Opin Pharmacother; 2020 Feb; 21(2):167-172. PubMed ID: 31762335
    [Abstract] [Full Text] [Related]

  • 16. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
    Jackson VM, Price DA, Carpino PA.
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213
    [Abstract] [Full Text] [Related]

  • 17. Liraglutide in the treatment of obesity.
    Ng SY, Wilding JP.
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacological management of obesity in pediatric patients.
    Boland CL, Harris JB, Harris KB.
    Ann Pharmacother; 2015 Feb; 49(2):220-32. PubMed ID: 25366340
    [Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of new-generation anti-obesity medications: a narrative review.
    Patel DK, Stanford FC.
    Postgrad Med; 2018 Mar; 130(2):173-182. PubMed ID: 29388462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.